CIK 0001919246
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Pelthos Therapeutics Inc.
Sign in to watch- Ticker
- PTHS
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 863335449
- Phone
- +1 919-908-2422
- Business address
- 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM, NC, 27703
- Former names
- Channel Therapeutics Corp, Chromocell Therapeutics Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $44,939
- in 3 filings, $45K under 10b5-1 plans
Net −$44,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-17 | LIGAND PHARMACEUTICALS INC Director | Returned to the company · Senior Secured Convertible Note | −0 | 0 | ||
| 2025-12-17 | LIGAND PHARMACEUTICALS INC Director | Grant or award · Senior Secured Convertible Note | +0 | |||
| 2025-11-06 | LIGAND PHARMACEUTICALS INC Director | Grant or award · Senior Secured Convertible Note | +0 | $9,000,000.00 | $0 | |
| 2025-07-01 | LIGAND PHARMACEUTICALS INC 10% owner | Conversion | +1,500,000 | $10.00 | $15.0M | 1,500,000 |
| 2025-07-01 | LIGAND PHARMACEUTICALS INC 10% owner | Conversion · Series A Convertible Preferred Stock | −15,000 | 3,000 | ||
| 2025-07-01 | LIGAND PHARMACEUTICALS INC 10% owner | Other acquisition · Series A Convertible Preferred Stock | +31,278.68 | 34,278.68 |
Page 1 of 1 · 6 trades